illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Blau Farmaceutica
Company logo

Blau Farmaceutica | Sustainability Performance

https://www.blau.com/

A pharmaceutical company involved in the research, production, and commercialization of specialty medicines. Its portfolio includes injectable drugs and biological products aimed at hospital and institutional use, with operations extending across several countries.

1987

Brazil

1,001 - 5,000 employees

Pharmaceuticals

$100M - 500M in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#9124
Overall
#129
in Brazil
#212
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Rede D'Or Sao Luiz

Brazil, Health Care, Hospital & Health Care


Company logo
Femme

Brazil, Health Care, Biotechnology


Company logo
Opy Health

Brazil, Health Care, Hospital & Health Care

Market cap

2.5B $, 2026▲3.3% YoY

Revenue

1.8B $, 2024▼21.8% YoY

R&D intensity

1.71% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

2.5B $, 2026▲3.3% YoY

Revenue

1.8B $, FY2024▼21.8% YoY

EBITDA

328.0M $, FY2024▼9.1% YoY

Operating margin

19% Industry: -33▲28% YoY

P/E ratio

8.3 Industry: 26▲8.5% YoY

Revenue & EBITDA

$1.8BFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

223.4M 2024▼119.6% YoY

Capex

283.0M 2024▼6.7% YoY

Debt/equity ratio

0.2 Industry: 0▼NaN% YoY

R&D intensity

1.7%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

1.4

▼ 10.0%

2022

1.4

▼ 3.2%

2023

1.8

▼ 2.4%

2024

4.4

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

0%
Independent Directors

0 out of 10 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


Total sustainability employees

11+


    Available in
    Scale package

    Access
  • Email

  • Email